AstraZeneca agreed to pay up to $1.5 billion to acquire exclusive worldwide development and sales rights for Dizal Pharmaceutical’s oral EGFR lung cancer drug Zegfrovy (sunvozertinib). The payment structure includes $600 million upfront plus development and sales milestones, with tiered royalties. The deal follows positive Phase 3 results from the Wu-Kong28 trial in first-line non-small cell lung cancer with EGFR exon 20 insertion mutations. AstraZeneca said it intends to add Zegfrovy to its EGFR-mutated portfolio as Dizal also filed for label expansion in the US and China. For biotech partnerships, the timing matters: it signals that global pharma is willing to underwrite rights on the back of late-stage mutation-specific efficacy data, even after previous setbacks in competing EGFR exon 20 strategies. For Dizal, it changes the scale of commercial capability and reduces execution risk ahead of potential regulatory decisions.